NCT02365597 2026-03-19
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT03036098 2026-03-06
CheckMate901
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03390504 2026-02-02
THOR
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05645692 2026-01-30
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT02516241 2026-01-28
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT07207928 2026-01-09
AvePem
Azienda Ospedaliera Universitaria Integrata Verona
Completed
NCT05366725 2025-12-02
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT04223856 2025-06-13
EV-302
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03425201 2024-12-31
NICARAGUA
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 1/2 Completed
NCT02891161 2024-11-27
DUART
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT02033993 2023-08-22
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
Canadian Cancer Trials Group
Phase 2 Completed
NCT04131634 2021-06-16
SAbR
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT00790426 2020-12-19
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
Novartis
Phase 2 Completed
NCT00821327 2016-10-25
Gemzar, Cisp, Sunitinib Urothelial Ca
US Oncology Research
Phase 2 Completed
NCT01801137 2016-06-21
AFINIVEST
Hopital Foch
Phase 2 Completed